Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells $137,219.20 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki L. Sato sold 10,960 shares of the company’s stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total value of $137,219.20. Following the sale, the director now owns 1,312,391 shares of the company’s stock, valued at approximately $16,431,135.32. The trade was a 0.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Vir Biotechnology Stock Down 3.0 %

Shares of VIR stock opened at $12.10 on Friday. Vir Biotechnology, Inc. has a twelve month low of $6.56 and a twelve month high of $14.45. The company has a market cap of $1.67 billion, a P/E ratio of -3.09 and a beta of 0.51. The business has a fifty day simple moving average of $8.24 and a 200 day simple moving average of $8.36.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business had revenue of $2.38 million for the quarter, compared to the consensus estimate of $5.54 million. During the same quarter in the prior year, the company earned ($1.22) earnings per share. Vir Biotechnology’s quarterly revenue was down 9.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Vir Biotechnology, Inc. will post -3.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a research report on Friday. Morgan Stanley upgraded Vir Biotechnology from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $10.00 to $20.00 in a research report on Thursday. JPMorgan Chase & Co. upped their target price on Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a research report on Thursday. Needham & Company LLC reiterated a “buy” rating and set a $19.00 target price on shares of Vir Biotechnology in a research report on Wednesday, November 20th. Finally, Barclays cut their target price on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.80.

Hedge Funds Weigh In On Vir Biotechnology

Several large investors have recently bought and sold shares of the company. Barclays PLC raised its position in Vir Biotechnology by 1.3% in the third quarter. Barclays PLC now owns 550,186 shares of the company’s stock valued at $4,121,000 after purchasing an additional 7,287 shares during the last quarter. State Street Corp raised its position in Vir Biotechnology by 10.4% in the third quarter. State Street Corp now owns 5,625,533 shares of the company’s stock valued at $42,135,000 after purchasing an additional 530,645 shares during the last quarter. Quarry LP raised its position in Vir Biotechnology by 901.8% in the third quarter. Quarry LP now owns 17,000 shares of the company’s stock valued at $127,000 after purchasing an additional 15,303 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in Vir Biotechnology by 10.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 350,265 shares of the company’s stock valued at $2,623,000 after purchasing an additional 33,473 shares during the last quarter. Finally, Erste Asset Management GmbH bought a new position in Vir Biotechnology in the third quarter valued at about $217,000. 65.32% of the stock is currently owned by institutional investors.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).